Impact statement

Precision medicine holds great promise to personalize medical therapies and treatments for each patient in order to improve clinical outcomes of disease. However, there remains hesitation among patients who may be unfamiliar with this promising technology. To engage pediatric patient participation in the use of clinical precision medicine, receiving patient consent is required. Given the variance in consent models in pediatric medicine due to regional contexts with no standardized international guidelines, we provide a clinical primer of existing informed consent workflows and promising modern adaptations to informed consent in pediatric precision medicine. This article serves as a call to action for renewed discussion toward standardized frameworks for informed consent in pediatric patient populations.

Informed consent frameworks

Decision-making in pediatric precision medicine is a balance of priorities between respecting the pediatric patient’s self-determination and making the most optimal decisions to improve care from the healthcare provider and surrogate decision-maker perspectives. Informed consent is defined as the voluntary, autonomous authorization of medical intervention by a patient with the capacity to understand and appreciate disclosed information relevant to the intervention (Del Carmen and Joffe, Reference Del Carmen and Joffe2005). The clinical workflow of precision medicine starts with requesting informed consent from the pediatric patient or their substitute decision-makers when appropriate. Substitute decision-makers are individuals, such as parents, guardians, family members and individuals with power of attorney in pediatric medicine, with legal power to authorize healthcare-related decisions on another’s behalf if they cannot make the decisions for themselves, such as in the case of minors without knowledge and emotional understanding of the proposed intervention (Sellars et al., Reference Sellars, Tran, Nolte, White, Sinclair, Fetherstonhaugh and Detering2021). Decision-makers providing consent to precision medicine must assess the value of genetic screening while considering the current severity of the patient’s disease, the onset of future symptoms and the efficacy of follow-up treatment that follows from screening.

Age-based informed consent models have traditionally separated pediatric patients into two or more cohorts stratified by age, where patients below a pre-specified age threshold require joint consent to treatment from their surrogate decision-maker or assent to participate in the care plan, and patients above the threshold can provide informed consent independently (Coughlin, Reference Coughlin2018). Beyond using age as a threshold measure of capacity to consent, the interplay between subjective factors such as patient maturity and previous ability to make medical decisions based on absolute risk should also be considered along with objective factors such as patient age to determine the patient’s holistic capacity to give informed consent for genetic testing (Salibian et al., Reference Salibian, Frey, Choi and Karp2018).

In the case of children incapable of providing informed consent, a common normative standard used to guide substitute decision-making is the best interests principle, where decisions are informed by the patient’s best interests (Hall et al., Reference Hall, Chowdhury, Pashayan, Hallowell, Pharoah and Burton2014). The best interests standard for informed consent has been challenged by proponents for an alternative framework that supposes parents have an ethical right to guide medical decisions for their children, even if they do not maximize their child’s well-being. Known as the zone of parental discretion, this ethical approach applies when parents may disagree with physicians over the recommendation for treatment and refuse to provide consent, so long as the child is not significantly harmed (Gillam, Reference Gillam2016).

Alternative frameworks of informed consent have focused on allowing parents to choose from reasonable options within an acceptable harm threshold or replacing substitute decision-making with supportive decision-making that establishes the patients as the primary decision-maker regardless of mental capacity (Diekema, Reference Diekema2004).

Pediatric patients who are not capable of consenting on their own behalf should provide assent, which allows for increased participation from pediatric participants with developing capacity to agree to proposed care. Assent is defined as the interactive process involving the disclosure of cognitively and emotionally appropriate information to the minor about the medical intervention and the voluntary agreement to choose to participate in the intervention free of undue influence (Tait and Geisser, Reference Tait and Geisser2017).

Assent empowers children to participate in the sharing decision-making process based on their developmental maturity and provides an opportunity for them to consider all of their options. To do so, children must be able to understand the details, benefits and risks of the procedure being performed, voluntarily decide to undergo the procedure, and communicate this choice (Rossi et al., Reference Rossi, Reynolds and Nelson2003). In shared decision-making frameworks involving pediatric assent, several ethical problems and burdens remain that require further research.

First, the age by which children should provide assent depends on a case-by-case evaluation of the patient’s developmental maturity, but previous research studies have required assent from patients ranging from 6 years old (Nunes et al., Reference Nunes, Ribeiro, Niewiadonski, Sabino, Yamamoto, Bertola, Gaburo and da Silva Filho2017), 12 years old (Hein et al., Reference Hein, De Vries, Troost, Meynen, Van Goudoever and Lindauer2015) and up to the age of majority based on regional legal guidelines (Coughlin, Reference Coughlin2018). The age of medical consent varies based on local contexts; for instance, the age of medical consent is 16 years in Spain and Scotland, 18 years in Italy and France, assessed based on maturity until the age of majority in the United Kingdom and assessed based on maturity even beyond the age of majority at 18 years in Finland and Sweden (Bolcato et al., Reference Bolcato, Franzetti, Fassina, Basile, Martinez and Tronconi2024). In Canada, provincial laws do not stipulate age of consent for treatment but generally deem minors (ranging from 14 to 16 years of age based on province) to have the capacity to make healthcare decisions (Coughlin, Reference Coughlin2018).

Using age as an indicator for patient capacity has previously been challenged by opponents who suggest that pediatric patients with more early lived experiences in healthcare, such as in the case of chronic disease, may have a more mature mindset when evaluating healthcare treatment options (Miller, Reference Miller2018). Second, there remains the need for education of both clinicians about the utility and application of assent as well as of patients and their substituted decision-makers about shared decision-making. Clinicians may have limited explicit knowledge of the concept of assent for medical treatment (Lee et al., Reference Lee, Havens, Sato, Hoffman and Leuthner2006), motivating the need for continuing clinical education about ethical concepts to remain up-to-date about modern consent practices. For patients, age-appropriate models may be needed to help minors and their substitute decision-makers understand the concept of assent and their roles in the process (Weisleder, Reference Weisleder2020). Maximizing the relevant, lay information necessary to understand the risk–benefit profiles of planned medical procedures coupled with novel communication mediums (Koonrungsesomboon et al., Reference Koonrungsesomboon, Charoenkwan, Natesirinilkul, Fanhchaksai, Sakuludomkan and Morakote2022), such as using age-appropriate multimedia assent documents (Wongthai et al., Reference Wongthai, Photia, Traivaree, Monsereenusorn, Lertvivatpong, Sudnawa and Rujkijyanont2022), are one step toward addressing this need for patient education. Third, there can exist exceptional scenarios where seeking assent from children with developing capacity may be overridden if there exists a significant benefit to the child and their wellbeing would be jeopardized otherwise (Moran et al., Reference Moran, Thornburg and Barfield2011). However, we note that critiques of assent due to its heterogeneous conceptual definition may lead to the potential for harm to specific groups, such as when a minor’s dissent is ignored due to parental insistence for treatment (Wongthai et al., Reference Wongthai, Photia, Traivaree, Monsereenusorn, Lertvivatpong, Sudnawa and Rujkijyanont2022). Loco-regional definitions of assent procedures should be consistently applied whenever possible in consultation with interdisciplinary care teams to standardize norms for assent.

Given that patient participation in precision medicine can be associated with their voluntary enrollment in related clinical trials, oversight of clinical studies by local ethics review boards remains a necessary stakeholder in the supervision of precision medicine research. The ethics review board is in the position to define the components of the informed consent processes and should ensure that such processes can be readily understood by a lay audience, such as minors and their substitute decision-makers (Matrana and Campbell, Reference Matrana and Campbell2020). In addition, review boards play an integral role in the long-term oversight of precision medicine trial-related data governance and privacy, as defined in the terms of consent (Chen, Reference Chen2020). Taken together, ethics review boards also play an emergent role in precision medicine due to the marked overlap between medical therapy and clinical research studies in precision medicine.

Modern adaptations to improve informed consent practices

Modern consent workflows have recently been proposed to address the practical challenges to informed consent due to the unclear expectations of the benefits of precision medicine, the change in development capacity when patients reach the age of majority, and the overwhelming demands from repeated consent requests. First, having a two-step consent process where consent to genetic screening occurs one to two months following the initial consent for a diagnostic biopsy may increase the ability for parents of children to provide meaningful informed consent (Oberg et al., Reference Oberg, Glade Bender, Cohn, Morris, Ruiz, Chung, Appelbaum, Kung and Levine2015). This two-step approach gives parents and children time and space to fully process the implications of genetic screening. Second, providing options for pediatric patients to exercise their right to re-consent for continued use of genomic data at the age of majority aligns with the patient’s right to autonomy when full informed decision-making capacity has developed (Edwards et al., Reference Edwards, Korngiebel, Pfeifer, Goodman, Renz, Wenzel, Bowen and Condit2016). Third, broad consent has previously been proposed as one way for pediatric patients and their parents to provide a one-time informed consent for the reuse of genomic data and/or health information in future research as deemed appropriate by a regulatory oversight body (Smith et al., Reference Smith, Sanderson, Brothers, Myers, McCormick, Aufox, Shrubsole, Garrison, Mercaldo, Schildcrout and Clayton2016). When the mature child and parents are ready to make a decision about genetic testing for adult-onset conditions, factors such as the disease, the stage of development of the child, family dynamics and values should be considered. The conceptual development of dynamic consent frameworks in precision medicine to support both specific and broad, blanket consent is one step toward personalizing consent processes to the unique preferences of minors and their substitute decision-makers (Goncharov et al., Reference Goncharov, Suominen and Cook2022).

The age-appropriate information provided to pediatric patients and their legal representatives should, at a minimum, explain the purpose of the proposed precision medicine approach, who will have access to the genomic data, and provide clear written forms for providing informed consent (Naito et al., Reference Naito, Aburatani, Amano, Baba, Furukawa, Hayashida, Hiyama, Ikeda, Kanai, Kato and Kinoshita2021). Genetic counseling should be provided to both the substitute decision-maker and the child about primary, clinically actionable findings and the potential for incidental findings with unknown impact to protect the patient’s right to know and not know (Naito et al., Reference Naito, Aburatani, Amano, Baba, Furukawa, Hayashida, Hiyama, Ikeda, Kanai, Kato and Kinoshita2021). We highlight the distinction between genomic testing for evidence-based, clinically actionable findings with proven therapeutic implications compared to incidental findings, such as variants of unknown significance identified in exploratory, whole genome-scale research. Incidental findings remain commonplace in precision medicine fields such as clinical genomics, with an ongoing debate about the duty to report incidental findings based on perceived risks of disease threat (AlFayyad et al., Reference AlFayyad, Al-Tannir, Abu-Shaheen and AlGhamdi2021). Incidental findings may harbor unexpected results that require further high clinical suspicion for their relevance and applicability to clinical treatment, given their potential to cause patient anxiety over lack of actionability. To do so, engagement in genetic counseling, verification of results with the molecular genetics laboratory, and exploring patient perspectives over their right to know and not know remain ethical priorities (Maani et al., Reference Maani, Panabaker, JM, Buckley, Semotiuk, Farncombe, Ainsworth, Panchal, Sadikovic, Armel and Lin2021). Despite the need for genetic counselors to navigate the complex medical and ethical considerations of pediatric precision medicine, there remains a shortage of genetic counselors and related clinicians necessary to meet the demands for precision medicine testing (Dragojlovic et al., Reference Dragojlovic, Borle, Kopac, Ellis, Birch, Adam, Friedman, Nisselle, Elliott and Lynd2020). Revisions aimed at developing more efficient contemporary genetic service models, including education to improve the competency of healthcare learners and providers in precision medicine-related tasks (Chen and Gorla, Reference Chen and Gorla2023), such as risk assessments and taking family histories, as well as automation of tasks through tools such as electronic decision aids and artificial intelligence, remain an ongoing area of research (Dragojlovic et al., Reference Dragojlovic, Borle, Kopac, Ellis, Birch, Adam, Friedman, Nisselle, Elliott and Lynd2020).

Notably, a review of patient perspectives related to ethical issues in precision medicine by Ahmed et al. (Reference Ahmed, Constantinidou and Chatzittofis2023) identified several emergent themes, including data governance, patient costs, risks for discrimination, issues with the diagnostic accuracy and psychosocial implications of the findings. Future research is needed to evaluate how these ethical issues can be addressed in part through revised informed consent processes, with a particular emphasis on the need to consider pediatric patients as a growing patient population involved in precision medicine. Upon reviewing the contemporary literature on ethics in consent-related practices of pediatric precision medicine, we synthesized a list of themes that can be included as topics of discussion at the time of consent in Table 1.

Table 1. Discussion themes during pediatric precision medicine consent